RLAY Stock Forecast & Price Target

Relay Therapeutics is viewed positively because its Dynamo platform is producing differentiated clinical signals in hard-to-drug targets, most notably zovegalisib in vascular anomalies and breast cancer. The company’s catalyst-rich setup is supported by a strong balance sheet, with $910.9M in cash at 2Q26 expected to fund operations into 2029, while 24.51% short interest creates asymmetric upside if upcoming regulatory or data updates validate the current results. The combination of a potentially large commercial opportunity, encouraging efficacy such as a 44% ORR in later-line triplet therapy, and a 109-patient pooled dataset in 2L breast cancer underpins a constructive long-term outlook.

Relay Therapeutics is a high-risk clinical-stage company whose valuation depends heavily on speculative DCF assumptions, including a 75% probability of approval for zovegalisib and a 10% discount rate, yet even this framework only supports a $6.2B to $6.3B projected market value. The fundamental concern is that its pipeline still faces meaningful clinical, regulatory, and competitive uncertainty, with the cited risks of negative data, trial delays, approval failure, and weaker-than-expected commercial uptake all capable of impairing value. On top of that, the expectation of additional equity financing to fund development creates medium- to long-term dilution risk, making the stock less attractive despite the company’s precision-medicine platform and oncology-focused pipeline.